文献速递炎症性肠病

乌司奴单抗维持期谷浓度与溃疡性结肠炎临床、生物学、内镜及组织学缓解的相关性

Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2022-05-04

这项多中心横断面研究纳入52例接受戈利木单抗维持治疗的溃疡性结肠炎患者,发现达到临床缓解、内镜愈合、组织学缓解及疾病清除者的戈利木单抗谷浓度中位数显著更高,并识别出与各结局相关的最佳谷浓度阈值。

要点

  • 临床缓解者戈利木单抗谷浓度中位数2.01 μg/ml,未缓解者0.72 μg/ml(p=0.047)。
  • 内镜愈合(Mayo内镜子评分0)者谷浓度中位数2.52 μg/ml,未愈合者1.47 μg/ml(p=0.003)。
  • 随访期间避免剂量升级或停药者谷浓度中位数2.24 μg/ml,发生者0.98 μg/ml(p=0.012)。

核心结论

  • 维持期戈利木单抗谷浓度与包括内镜愈合、组织学缓解及长期持续用药在内的良好治疗结局相关。
  • 研究识别出与关键结局最密切相关的戈利木单抗最佳谷浓度阈值。

研究设计与样本

  • 多中心横断面研究,纳入52例接受戈利木单抗维持治疗的溃疡性结肠炎患者,招募时处于缓解期或发作期。
  • 安排结肠镜检查,并进行研究特异性直肠结肠活检用于盲法中心组织学判读。
  • 在结肠镜检查前后采集戈利木单抗谷浓度样本。

主要发现

  • 临床缓解者戈利木单抗谷浓度中位数2.01 μg/ml vs 未缓解者0.72 μg/ml(p=0.047)。
  • 临床-生化联合缓解(PMS≤2且粪便钙卫蛋白<250 μg/g)者2.21 μg/ml vs 未达者1.47 μg/ml(p=0.041)。
  • 内镜愈合(Mayo内镜子评分0)者2.52 μg/ml vs 未愈合者1.47 μg/ml(p=0.003)。
  • 组织学缓解(Geboes指数≤2.0)者2.33 μg/ml vs 未缓解者1.50 μg/ml(p=0.02)。
  • 疾病清除(临床缓解+内镜愈合+组织学缓解)者2.52 μg/ml vs 未达者1.70 μg/ml(p=0.009)。

关键数值与推荐

  • 临床缓解相关阈值为0.85 μg/ml(AUC 0.76)。
  • 联合缓解相关阈值为1.90 μg/ml(AUC 0.76)。
  • 内镜愈合相关阈值为2.29 μg/ml(AUC 0.75)。
  • 组织学缓解相关阈值为1.79 μg/ml(AUC 0.68)。
  • 疾病清除相关阈值为2.29 μg/ml(AUC 0.72),长期无事件持续用药相关阈值为1.56 μg/ml(AUC 0.71)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimal golimumab concentration thresholds for important outcomes during maintenance are lacking. AIMS: To investigate the association of golimumab trough concentrations during maintenance with key outcomes, including endoscopic and histologic remission, and long-term event-free persistence with golimumab, in patients with UC. METHODS: This multi-centre, cross-sectional study included patients with UC on golimumab maintenance recruited either in remission or during a flare. Colonoscopy was scheduled, and study-specific rectocolonic biopsies were taken for blind central histologic reading. Samples for golimumab trough concentrations were collected close to colonoscopy. RESULTS: Fifty-two patients were included. Median golimumab trough concentrations (μg/ml) were significantly higher in patients who had clinical remission (2.01 vs. 0.72, p = 0.047), combined clinical-biochemical remission (PMS ≤2 + faecal calprotectin <250 μg/g) (2.21 vs. 1.47, p = 0.041), endoscopic healing (Mayo endoscopic subscore 0) (2.52 vs. 1.47, p = 0.003), histologic remission (Geboes index ≤2.0) (2.33 vs. 1.50, p = 0.02) and disease clearance (clinical remission endoscopic healing + histologic remission) (2.52 vs. 1.70, p = 0.009), compared with those not meeting these criteria. Golimumab concentrations were significantly higher in patients who avoided golimumab dose escalation/discontinuation during follow-up (2.24 vs. 0.98, p = 0.012). Receiver-operating characteristic analyses identified golimumab thresholds [area under the curve] of 0.85 [0.76], 1.90 [0.76], 2.29 [0.75], 1.79 [0.68], 2.29 [0.72] and 1.56 [0.71] μg/ml as associated with clinical remission, combined remission, endoscopic healing, histologic remission, disease clearance and long-term event-free persistence with golimumab, respectively. CONCLUSIONS: Golimumab trough concentrations during maintenance are associated with favourable treatment outcomes including endoscopic healing, histologic remission and long-term persistence on golimumab. We identified the optimal golimumab thresholds most closely associated with key outcomes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Taxonera C, Fernández-Aceñero MJ, Olivares D, et al. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis. Aliment Pharmacol Ther. 2022. PMID: 35509152. doi:10.1111/apt.16964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。